Antibody drugs and diagnostics have changed the face of modern medicine, yet high development costs, complex manufacturing processes and relatively poor stability restrict their potential. OBodies are a new class of high-specificity binding proteins with several important advantages over the conventional antibody approach. OBodies' novel platform technology is based on a small, ubiquitous protein domain, the OB-domain. In nature, the OB-domain has evolved as a highly flexible binding domain, found in a wide variety of functional roles. We are able to exploit this natural flexibility, by selecting a candidate domain from the appropriate organism and engineering high target specificity and affinity. Proprietary libraries based on human and thermophillic bacterial OB-domains are under development for human therapeutics and diagnostics, respectively.
- Clinical diagnostics
- Point-of-care diagnostics
- Medical therapeutics
- Research tools
- Significantly smaller than traditional antibodies and antibody fragments.
- High stability, which means OBodies don't require refrigeration as antibodies do.
- Broad range of applications due to small size and high specificity.
OBodies is seeking investment, partnerships and collaborations to advance the technology through to market ready.
Proof of Concept